Shanghai Allink Biotherapeutics Co., Ltd.

This phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …

This study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find th…